Blinded and unblinded internal pilot study designs for clinical trials with count data

Internal pilot studies are a popular design feature to address uncertainties in the sample size calculations caused by vague information on nuisance parameters. Despite their popularity, only very recently blinded sample size reestimation procedures for trials with count data were proposed and their properties systematically investigated. Although blinded procedures are favored by regulatory authorities, practical application is somewhat limited by fears that blinded procedures are prone to bias if the treatment effect was misspecified in the planning. Here, we compare unblinded and blinded procedures with respect to bias, error rates, and sample size distribution. We find that both procedures maintain the desired power and that the unblinded procedure is slightly liberal whereas the actual significance level of the blinded procedure is close to the nominal level. Furthermore, we show that in situations where uncertainty about the assumed treatment effect exists, the blinded estimator of the control event rate is biased in contrast to the unblinded estimator, which results in differences in mean sample sizes in favor of the unblinded procedure. However, these differences are rather small compared to the deviations of the mean sample sizes from the sample size required to detect the true, but unknown effect. We demonstrate that the variation of the sample size resulting from the blinded procedure is in many practically relevant situations considerably smaller than the one of the unblinded procedures. The methods are extended to overdispersed counts using a quasi-likelihood approach and are illustrated by trials in relapsing multiple sclerosis.

[1]  Richard Nicholas,et al.  Considerations in the design of clinical trials for relapsing multiple sclerosis , 2012 .

[2]  J. Wittes,et al.  The role of internal pilot studies in increasing the efficiency of clinical trials. , 1990, Statistics in medicine.

[3]  C Jennison,et al.  Estimating the sample size for a t-test using an internal pilot. , 1999, Statistics in medicine.

[4]  Heinz Schmidli,et al.  Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis , 2010, Statistics in medicine.

[5]  Meinhard Kieser,et al.  Blinded Sample Size Reestimation in Multiarmed Clinical Trials , 2000 .

[6]  H Merabet,et al.  The design and analysis of sequential clinical trials , 2013 .

[7]  A Whitehead,et al.  Mid-trial design reviews for sequential clinical trials. , 2001, Statistics in medicine.

[8]  G. Wassmer,et al.  Comments on the Draft Guidance on “Adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration , 2010, Journal of biopharmaceutical statistics.

[9]  Ludwig Kappos,et al.  Placebo-controlled trial of oral laquinimod for multiple sclerosis. , 2012, The New England journal of medicine.

[10]  Draft Guidance Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE , 2010 .

[11]  T. Friede,et al.  A comparison of methods for adaptive sample size adjustment , 2001, Statistics in medicine.

[12]  Heinz Schmidli,et al.  Robustness of methods for blinded sample size re‐estimation with overdispersed count data , 2013, Statistics in medicine.

[13]  T. Friede,et al.  Re-calculating the sample size in internal pilot study designs with control of the type I error rate. , 2000, Statistics in medicine.

[14]  B. Turnbull,et al.  Group Sequential Methods with Applications to Clinical Trials , 1999 .

[15]  Frank Miller,et al.  Variance Estimation in Clinical Studies with Interim Sample Size Reestimation , 2005, Biometrics.

[16]  Michael A Proschan,et al.  Sample size re‐estimation in clinical trials , 2009, Biometrical journal. Biometrische Zeitschrift.

[17]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[18]  Richard J Cook,et al.  Two‐stage design of clinical trials involving recurrent events , 2009, Statistics in medicine.

[19]  Richard Nicholas,et al.  Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis , 2012, Multiple sclerosis.

[20]  B. A. de Jong,et al.  Placebo-controlled trial of oral laquinimod for multiple sclerosis , 1836 .

[21]  Michael A Proschan,et al.  Two-Stage Sample Size Re-Estimation Based on a Nuisance Parameter: A Review , 2005, Journal of biopharmaceutical statistics.

[22]  Meinhard Kieser,et al.  Sample Size Recalculation in Internal Pilot Study Designs: A Review , 2006, Biometrical journal. Biometrische Zeitschrift.

[23]  Meinhard Kieser,et al.  Blinded sample size re‐estimation in superiority and noninferiority trials: bias versus variance in variance estimation , 2013, Pharmaceutical statistics.

[24]  T Friede,et al.  Blinded Sample Size Reestimation with Negative Binomial Counts in Superiority and Non-inferiority Trials , 2010, Methods of Information in Medicine.

[25]  P. McCullagh,et al.  Generalized Linear Models, 2nd Edn. , 1990 .

[26]  K E Muller,et al.  Controlling test size while gaining the benefits of an internal pilot design. , 2001, Biometrics.

[27]  Liming Xiang,et al.  Sensitivity of Test for Overdispersion in Poisson Regression , 2005, Biometrical journal. Biometrische Zeitschrift.